<DOC>
	<DOCNO>NCT01839110</DOCNO>
	<brief_summary>This study look see give ranolazine subject stable pulmonary hypertension specific therapy right ventricular dysfunction ( RVEF &lt; 45 % ) would improve outcome . This study accompany baseline comparison metabolic profiling/microRNA/iPS cell subject without right ventricular dysfunction .</brief_summary>
	<brief_title>Targeting Right Ventricle Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Right</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Symptomatic pulmonary hypertension base one follow criterion : Idiopathic pulmonary arterial hypertension , Familial pulmonary arterial hypertension , pulmonary hypertension associate connective tissue disease , chronic thromboembolic pulmonary hypertensionnonsurgical/distal vessel disease patient reluctant go surgery within 6month period willing participate , simple congenital repair atrial septal defect ventricular septal defect unrepaired small atrial septal defect ventricular septal defect persistent proportion pulmonary arterial hypertension , group 3 patient component pulmonary arterial hypertension , pulmonary arterial hypertension cause condition affect vein small vessel lung , sickle cell disease , group 5 pulmonary hypertension polycythemia vera , essential thrombocythemia , sarcoidosis , vasculitis , metabolic disorder . WHO functional class II , III , IV Mean pulmonary artery pressure &gt; 25 mmHg rest Pulmonary capillary wedge pressure leave ventricular end diastolic pressure &lt; 15 mmHg Baseline 6minute walk test distance &gt; 50 meter Stable baseline exist PH specific therapy 12 week dosage change within 28 day prior screen . Previous treatment prior sensitivity ranolazine Any family history correct QT interval prolongation , congenital long QT syndrome , receive drug prolong correct QT interval Parenchymal lung disease show total lung capacity &lt; 50 % predict OR force expiratory volume one second/forced vital capacity &lt; 50 % Portal hypertension associate liver disease Left side heart disease include follow : moderate great aortic mitral valve disease , Any leave ventricle cardiomyopathy , Left ventricular systolic dysfunction define ejection fraction &lt; 50 % , Symptomatic coronary artery disease Uncontrolled hypertension Uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>right ventricular function</keyword>
	<keyword>ranolazine</keyword>
</DOC>